UNSPSC 51283947: Sulfadiazine sodium

This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H9N4O2S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84CS1P306F, chemically known as trisulfapyrimidine, oral suspension but more generally known as sulfadiazine sodium, which bears US NIH Compound Identifier 5215. European Medicines Agency schedules Sulfadiazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10696MIG.

UNSPSC 51283947 Sulfadiazine sodium is a Commodity code whose recent state and local procurement activity shows minimal alignment with its nominal pharmaceutical product scope. The four most recent opportunities posted under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products—none of which center on sulfadiazine sodium specifically. State and local governments using this code designation are sourcing a broad range of pharmaceutical, medical supply, and pharmacy benefit products rather than the specific antibiotic indicated by the code name. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP).

Recent opportunities span Florida, Texas, Minnesota, and Oregon, with activity concentrated in cooperative purchasing vehicles and formal competitive bids. Representative recent solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a due date of July 26, 2023 (note: this date appears inconsistent with the June 30, 2026 posted date); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract amount of $700,000 and a March 13, 2026 response deadline, featuring a sheltered-market set-aside for certified Small Local Business Enterprises with a 5% bid discount; MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and awards effective July 1, 2026; and the Texas HHS Commission's RFI for direct-to-manufacturer prescription capabilities, posted April 3, 2026, as preliminary market intelligence gathering. The code shows no meaningful recent activity specifically tied to sulfadiazine sodium procurement.